BAY 1007626

Drug Profile

BAY 1007626

Alternative Names: Progestin IUS - Bayer

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Hormonal contraceptives; Progesterone congeners
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pregnancy

Most Recent Events

  • 01 Jul 2016 Bayer completes a phase II trial in Contraception in Germany, Netherlands and United Kingdom (Intrauterine) (NCT02490774)
  • 27 Apr 2016 Bayer suspends enrolment in a phase II trial in Contraception in Germany, Netherlands and United Kingdom (Intrauterine) (NCT02490774)
  • 18 May 2015 Phase-II clinical trials in Pregnancy (Prevention) in Netherlands (Intrauterine)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top